Search
Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigationalMantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. … Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalLifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome).
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigationalreceived an ALK-inhibitor on December 18, 2024. … [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).
Categories: P-glycoprotein substratesRaloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigational[A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal … In addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene
Categories: Estrogen Receptor Modulators, P-glycoprotein substratesAntithrombin Alfa
go.drugbank.com/drugs/DB11166ApprovedAntithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations
Levodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalThe first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. … Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after
Mixtures: Zuades 5 mg/1,25 mg Tabletten zur Herstellung einer Suspension zum Einnehmen für ein Dosiergerät, LEVODOPA P BENS AL 100/25Ritonavir
go.drugbank.com/drugs/DB00503ApprovedInvestigationalThe inclusion of ritonavir can select for HIV-1 protease inhibitor resistance-associated substitutions. … While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseFerric sulfate
go.drugbank.com/drugs/DB11171ApprovedIt is produced by the reaction of sulfuric acid and an oxidizing agent.
Malathion
go.drugbank.com/drugs/DB00772ApprovedMalathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice. … Malathion is an irreversible cholinesterase inhibitor and has low human toxicity.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesBenzyl alcohol
go.drugbank.com/drugs/DB06770ApprovedInvestigationalMixtures: Skinsept pur - Lösung zur Anwendung auf der Haut, Skinsept color - Lösung zur Anwendung auf der HautCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates